Clywedog Therapeutics Announces Activation of All Centers and Patient Dosing in Multicenter, International Phase 1b Clinical Study of Balomenib in Type 2 Diabetes

DOVER, Del., Dec. 17, 2025 /PRNewswire/ -- Clywedog Therapeutics, Inc., a clinical-stage biotechnology company advancing novel therapies for metabolic diseases, today announced the activation of all clinical centers and patient dosing in its multicenter, international Phase 1b randomized, double-blind, placebo-controlled clinical study evaluating balomenib, a novel oral menin inhibitor, in adults with type 2 diabetes mellitus (T2DM).